NCT05850728View on ClinicalTrials.gov

First in Human Study of TLC-ART 101 (ACTU 2001)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Human Immunodeficiency VirusTreatmentAntiretroviral Therapy
Interventions
DRUG

TLC-ART

TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension

Trial Locations (1)

98104

UW Positve Research, Harborview Medical Center, Seattle

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Washington

OTHER